{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T08:44:16Z","timestamp":1775983456411,"version":"3.50.1"},"posted":{"date-parts":[[2025,3,26]]},"group-title":"Cell Biology","reference-count":72,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Proteasomes maintain cellular homeostasis by degrading abnormal proteins, while cancer cells exploit them for survival, becoming a key chemotherapeutic target. Bortezomib (BTZ), a reversible proteasomal inhibitor, is a front-line treatment for multiple myeloma, mantle cell lymphoma, and non-small cell lung cancer. However, its efficacy is limited by severe side effects, including neurotoxicity and cardiovascular distress, with its toxicity mechanisms largely unexplored. Here, we discover that Bortezomib (BTZ), is cytotoxic to non-cancerous cells distinctly from Carfilzomib (CFZ), the second-line irreversible PI. BTZ or CFZ is administered intravenously, impacting blood vessel (vascular) endothelial cells. We used human pulmonary microvascular endothelial cells (HPMECs) to demonstrate that BTZ but not CFZ elicits endoplasmic reticulum (ER) stress, mitochondrial membrane compromise, mitochondrial reactive oxygen species (ROS) accumulation, and Caspase (CASP)9 activation (mediator of Intrinsic apoptosis) within fifteen hours of treatment. By twenty-four hours, BTZ-treated cells display cleavage of CASP8 (mediator of extrinsic apoptosis), activation of CASP3 (terminal executioner of apoptosis), cell-death and vascular barrier loss. Pan-caspase inhibitor zVAD significantly rescues BTZ-treated cells from cytotoxicity. Both BTZ and CFZ effectively kill MM cells. These findings reveal novel insights into fundamental signaling of regular cells where reversible inhibition of the proteasome dictates a unique cascade of stress distinct from irreversible inhibition. These harmful effects of BTZ emphasize the need to re- evaluate its use as a frontline chemotherapy for MM.<\/jats:p>\n                <jats:sec>\n                  <jats:title>Graphical Abstract<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"645304v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Highlights<\/jats:title>\n                  <jats:list list-type=\"bullet\">\n                    <jats:list-item>\n                      <jats:p>Reversible proteasomal inhibitor Bortezomib is cytotoxic to non-cancerous, microvascular endothelial cells<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>In endothelial cells, Bortezomib, but not irreversible inhibitor Carfilzomib, activates temporal cascade of caspases (Caspase-9, Caspase-8, Caspase-3) triggering apoptosis<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>Caspase activation results from ER stress (via the IRE1\u03b1-CHOP) pathway and mitochondrial stress (ROS accumulation) independently from contribution from extrinsic signal via TNF<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>Bortezomib-dependent cytotoxicity compromises endothelial barrier potential<\/jats:p>\n                    <\/jats:list-item>\n                  <\/jats:list>\n                <\/jats:sec>","DOI":"10.1101\/2025.03.25.645304","type":"posted-content","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T09:35:19Z","timestamp":1742981719000},"source":"Crossref","is-referenced-by-count":0,"title":["Cancer Drug Bortezomib, a Proteasomal Inhibitor, Triggers Cytotoxicity in Microvascular Endothelial Cells via Multi-Organelle Stress"],"prefix":"10.64898","author":[{"given":"Prajakta","family":"Sawant","sequence":"first","affiliation":[{"name":"Doctoral Program in Biology (Molecular, Cellular & Developmental Biology), The Graduate Center, The City University of New York, New York, NY 10016, USA"},{"name":"Department of Biological Sciences, Bronx, Lehman College, The City University of New York, New York, NY 10468, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleena","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, Bronx, Lehman College, The City University of New York, New York, NY 10468, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Bensalel","sequence":"additional","affiliation":[{"name":"Doctoral Program in Biology (Molecular, Cellular & Developmental Biology), The Graduate Center, The City University of New York, New York, NY 10016, USA"},{"name":"Department of Biological Sciences, Bronx, Lehman College, The City University of New York, New York, NY 10468, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Gallego-Delgado","sequence":"additional","affiliation":[{"name":"Doctoral Program in Biology (Molecular, Cellular & Developmental Biology), The Graduate Center, The City University of New York, New York, NY 10016, USA"},{"name":"Department of Biological Sciences, Bronx, Lehman College, The City University of New York, New York, NY 10468, USA"},{"name":"Doctoral Program in Biochemistry, The Graduate Center, The City University of New York, New York, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratyusha","family":"Mandal","sequence":"additional","affiliation":[{"name":"Doctoral Program in Biology (Molecular, Cellular & Developmental Biology), The Graduate Center, The City University of New York, New York, NY 10016, USA"},{"name":"Department of Biological Sciences, Bronx, Lehman College, The City University of New York, New York, NY 10468, USA"},{"name":"Doctoral Program in Biochemistry, The Graduate Center, The City University of New York, New York, NY 10016, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026041200571456000_2025.03.25.645304v1.1","first-page":"1","article-title":"Structure, Dynamics and Function of the 26S Proteasome","volume":"6","year":"2021","journal-title":"Subcell Biochem"},{"key":"2026041200571456000_2025.03.25.645304v1.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.18.7071"},{"key":"2026041200571456000_2025.03.25.645304v1.3","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9707-8"},{"key":"2026041200571456000_2025.03.25.645304v1.4","doi-asserted-by":"publisher","DOI":"10.2174\/156800911794519752"},{"key":"2026041200571456000_2025.03.25.645304v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(75)90415-3"},{"issue":"1","key":"2026041200571456000_2025.03.25.645304v1.6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/16078454.2020.1784615","article-title":"The effect of rat nerve growth factor combined with vitamin B on peripheral neuropathy in multiple myeloma patients","volume":"25","year":"2020","journal-title":"Hematology"},{"key":"2026041200571456000_2025.03.25.645304v1.7","doi-asserted-by":"crossref","unstructured":"Pancheri, E. , et al., Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. Cancers (Basel), 2020. 12(9).","DOI":"10.3390\/cancers12092540"},{"issue":"6","key":"2026041200571456000_2025.03.25.645304v1.8","first-page":"407","article-title":"Bortezomib induced pulmonary toxicity: a case report and review of the literature","volume":"10","year":"2020","journal-title":"Am J Blood Res"},{"issue":"3","key":"2026041200571456000_2025.03.25.645304v1.9","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.3892\/ol.2016.4204","article-title":"Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review","volume":"11","year":"2016","journal-title":"Oncol Lett"},{"key":"2026041200571456000_2025.03.25.645304v1.10","first-page":"2913124","article-title":"Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature","volume":"2018","year":"2018","journal-title":"Case Rep Med"},{"key":"2026041200571456000_2025.03.25.645304v1.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1950"},{"key":"2026041200571456000_2025.03.25.645304v1.12","doi-asserted-by":"crossref","unstructured":"Crawford, L.J. , et al., Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res, 2006. 66(12): p. 6379 86.","DOI":"10.1158\/0008-5472.CAN-06-0605"},{"key":"2026041200571456000_2025.03.25.645304v1.13","unstructured":"Schwartz, R. and T. Davidson , Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park), 2004. 18(14 Suppl 11): p.14 21"},{"key":"2026041200571456000_2025.03.25.645304v1.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065888"},{"key":"2026041200571456000_2025.03.25.645304v1.15","doi-asserted-by":"publisher","DOI":"10.1186\/1747-1028-7-26"},{"key":"2026041200571456000_2025.03.25.645304v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1101-e255"},{"key":"2026041200571456000_2025.03.25.645304v1.17","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.01.004"},{"key":"2026041200571456000_2025.03.25.645304v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2009.09.004"},{"key":"2026041200571456000_2025.03.25.645304v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/nature09857"},{"key":"2026041200571456000_2025.03.25.645304v1.20","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14186"},{"issue":"6","key":"2026041200571456000_2025.03.25.645304v1.21","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.3109\/10428194.2011.637212","article-title":"Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed\/refractory multiple myeloma","volume":"53","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2026041200571456000_2025.03.25.645304v1.22","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0047"},{"key":"2026041200571456000_2025.03.25.645304v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2012.10.004"},{"key":"2026041200571456000_2025.03.25.645304v1.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2394"},{"key":"2026041200571456000_2025.03.25.645304v1.25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12967-016-0823-y","article-title":"Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells","volume":"14","year":"2016","journal-title":"J Transl Med"},{"issue":"17","key":"2026041200571456000_2025.03.25.645304v1.26","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.4155\/fmc-2018-0091","article-title":"Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition","volume":"10","year":"2018","journal-title":"Future Med Chem"},{"key":"2026041200571456000_2025.03.25.645304v1.27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003826"},{"issue":"1","key":"2026041200571456000_2025.03.25.645304v1.28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.21037\/tcr-21-2534","article-title":"Carfilzomib inhibits the proliferation and apoptosis of multiple myelomamcells by inhibiting STAT1\/COX-2\/iNOS signaling pathway","volume":"11","year":"2022","journal-title":"Transl Cancer Res"},{"key":"2026041200571456000_2025.03.25.645304v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.08.019"},{"key":"2026041200571456000_2025.03.25.645304v1.30","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3947"},{"key":"2026041200571456000_2025.03.25.645304v1.31","doi-asserted-by":"crossref","unstructured":"Caillot, M. , et al., Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death. Cancers (Basel), 2021. 13(10).","DOI":"10.3390\/cancers13102411"},{"key":"2026041200571456000_2025.03.25.645304v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-405881-1.00002-1"},{"key":"2026041200571456000_2025.03.25.645304v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2004.02.001"},{"key":"2026041200571456000_2025.03.25.645304v1.34","first-page":"237","article-title":"Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma","volume":"5","year":"2012","journal-title":"Onco Targets Ther"},{"key":"2026041200571456000_2025.03.25.645304v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"2026041200571456000_2025.03.25.645304v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.12.005"},{"issue":"5-6","key":"2026041200571456000_2025.03.25.645304v1.37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000448757","article-title":"Bortezomib Effects on Human Microvascular Endothelium in vitro","volume":"98","year":"2016","journal-title":"Pharmacology"},{"key":"2026041200571456000_2025.03.25.645304v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2009.11.005"},{"key":"2026041200571456000_2025.03.25.645304v1.39","doi-asserted-by":"crossref","unstructured":"Matsumoto, T. , et al., Bortezomib Increased Vascular Permeability by Decreasing Cell- Cell Junction Molecules in Human Pulmonary Microvascular Endothelial Cells.Int J Mol Sci, 2023. 24(13).","DOI":"10.3390\/ijms241310842"},{"issue":"12","key":"2026041200571456000_2025.03.25.645304v1.40","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/17474086.2017.1391088","article-title":"Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States","volume":"10","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"2026041200571456000_2025.03.25.645304v1.41","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-08-0108"},{"key":"2026041200571456000_2025.03.25.645304v1.42","doi-asserted-by":"crossref","unstructured":"Mandal, P. , et al., Multiple Autonomous Cell Death Suppression Strategies Ensure Cytomegalovirus Fitness. Viruses, 2021. 13(9).","DOI":"10.3390\/v13091707"},{"key":"2026041200571456000_2025.03.25.645304v1.43","doi-asserted-by":"crossref","first-page":"101502","DOI":"10.1016\/j.redox.2020.101502","article-title":"Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib","volume":"32","year":"2020","journal-title":"Redox Biol"},{"issue":"9","key":"2026041200571456000_2025.03.25.645304v1.44","doi-asserted-by":"crossref","first-page":"107676","DOI":"10.1016\/j.jbc.2024.107676","article-title":"Classical apoptotic stimulus, staurosporine, induces lytic inflammatory cell death, PANoptosis","volume":"300","year":"2024","journal-title":"J Biol Chem"},{"key":"2026041200571456000_2025.03.25.645304v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.10.021"},{"issue":"8","key":"2026041200571456000_2025.03.25.645304v1.46","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.bbamcr.2012.05.013","article-title":"zVAD-fmk upregulates caspase-9 cleavage and activity in etoposide-induced cell death of mouse embryonic fibroblasts","volume":"1823","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2026041200571456000_2025.03.25.645304v1.47","doi-asserted-by":"publisher","DOI":"10.2741\/2317"},{"key":"2026041200571456000_2025.03.25.645304v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(04)00156-X"},{"issue":"3","key":"2026041200571456000_2025.03.25.645304v1.49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12185-016-2016-0","article-title":"Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma","volume":"104","year":"2016","journal-title":"Int J Hematol"},{"key":"2026041200571456000_2025.03.25.645304v1.50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03083"},{"key":"2026041200571456000_2025.03.25.645304v1.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00611-0"},{"key":"2026041200571456000_2025.03.25.645304v1.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-019-0324-9"},{"key":"2026041200571456000_2025.03.25.645304v1.53","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a004424"},{"key":"2026041200571456000_2025.03.25.645304v1.54","doi-asserted-by":"publisher","DOI":"10.1159\/000495828"},{"key":"2026041200571456000_2025.03.25.645304v1.55","doi-asserted-by":"crossref","unstructured":"Mandal, P. , A.L. McCormick , and E.S. Mocarski , TNF Signaling Dictates Myeloid and Non-Myeloid Cell Crosstalk to Execute MCMV-Induced Extrinsic Apoptosis. Viruses, 2020. 12(11).","DOI":"10.3390\/v12111221"},{"key":"2026041200571456000_2025.03.25.645304v1.56","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0529-1"},{"key":"2026041200571456000_2025.03.25.645304v1.57","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M115.055376"},{"key":"2026041200571456000_2025.03.25.645304v1.58","doi-asserted-by":"publisher","DOI":"10.1101\/gad.6.3.439"},{"issue":"9","key":"2026041200571456000_2025.03.25.645304v1.59","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1021\/acs.chemrestox.6b00181","article-title":"Activating Transcription Factor 4 (ATF4)-ATF3-C\/EBP Homologous Protein (CHOP) Cascade Shows an Essential Role in the ER Stress-Induced Sensitization of Tetrachlorobenzoquinone-Challenged PC12 Cells to ROS-Mediated Apoptosis via Death Receptor 5 (DR5) Signaling","volume":"29","year":"2016","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"2026041200571456000_2025.03.25.645304v1.60","doi-asserted-by":"crossref","first-page":"101719","DOI":"10.1016\/j.jbc.2022.101719","article-title":"Inhibition of mitochondrial LonP1 protease by allosteric blockade of ATP binding and hydrolysis via CDDO and its derivatives","volume":"298","year":"2022","journal-title":"J Biol Chem"},{"key":"2026041200571456000_2025.03.25.645304v1.61","doi-asserted-by":"crossref","unstructured":"Zanini, G. , et al., The Role of Lonp1 on Mitochondrial Functions during Cardiovascular and Muscular Diseases. Antioxidants (Basel), 2023. 12(3).","DOI":"10.3390\/antiox12030598"},{"key":"2026041200571456000_2025.03.25.645304v1.62","first-page":"0175","article-title":"LonP1 Links Mitochondria-ER Interaction to Regulate Heart Function","volume":"6","year":"2023","journal-title":"Research (Wash D C"},{"issue":"6","key":"2026041200571456000_2025.03.25.645304v1.63","first-page":"1619","article-title":"Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2\/Omi","volume":"5","year":"2016","journal-title":"Toxicol Ref (Camb"},{"key":"2026041200571456000_2025.03.25.645304v1.64","unstructured":"Sharma, A. and C.V. Preuss , Bortezomib, in StatPearls. 2025: Treasure Island (FL)."},{"issue":"6","key":"2026041200571456000_2025.03.25.645304v1.65","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/kjm2.12835","article-title":"Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells","volume":"40","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"issue":"Suppl 35","key":"2026041200571456000_2025.03.25.645304v1.66","first-page":"S4296","article-title":"Cardiovascular adverse events in multiple myeloma patients","volume":"10","year":"2018","journal-title":"J Thorac Dis"},{"key":"2026041200571456000_2025.03.25.645304v1.67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01544.x"},{"issue":"9","key":"2026041200571456000_2025.03.25.645304v1.68","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00467-022-05802-z","article-title":"Endothelial dysfunction as a factor leading to arterial hypertension","volume":"38","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"2026041200571456000_2025.03.25.645304v1.69","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.jtha.2024.03.024","article-title":"The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium","volume":"22","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2026041200571456000_2025.03.25.645304v1.70","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvw047"},{"key":"2026041200571456000_2025.03.25.645304v1.71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.3323"},{"issue":"7","key":"2026041200571456000_2025.03.25.645304v1.72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620717710171","article-title":"The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma","volume":"8","year":"2017","journal-title":"Ther Adv Hematol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.03.25.645304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T07:57:28Z","timestamp":1775980648000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.03.25.645304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":72,"URL":"https:\/\/doi.org\/10.1101\/2025.03.25.645304","relation":{},"subject":[],"published":{"date-parts":[[2025,3,26]]},"subtype":"preprint"}}